250 related articles for article (PubMed ID: 30882891)
21. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
Reichardt P; Demetri GD; Gelderblom H; Rutkowski P; Im SA; Gupta S; Kang YK; Schöffski P; Schuette J; Soulières D; Blay JY; Goldstein D; Fly K; Huang X; Corsaro M; Lechuga MJ; Martini JF; Heinrich MC
BMC Cancer; 2016 Jan; 16():22. PubMed ID: 26772734
[TBL] [Abstract][Full Text] [Related]
22. Detecting Secondary C-KIT Mutations in the Peripheral Blood of Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor.
Wada N; Kurokawa Y; Takahashi T; Hamakawa T; Hirota S; Naka T; Miyazaki Y; Makino T; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
Oncology; 2016; 90(2):112-7. PubMed ID: 26779618
[TBL] [Abstract][Full Text] [Related]
23. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).
Dematteo RP; Gold JS; Saran L; Gönen M; Liau KH; Maki RG; Singer S; Besmer P; Brennan MF; Antonescu CR
Cancer; 2008 Feb; 112(3):608-15. PubMed ID: 18076015
[TBL] [Abstract][Full Text] [Related]
24. Characterizing gastrointestinal stromal tumors and evaluating neoadjuvant imatinib by sequencing of endoscopic ultrasound-biopsies.
Hedenström P; Nilsson B; Demir A; Andersson C; Enlund F; Nilsson O; Sadik R
World J Gastroenterol; 2017 Aug; 23(32):5925-5935. PubMed ID: 28932084
[TBL] [Abstract][Full Text] [Related]
25. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis.
Andersson J; Bümming P; Meis-Kindblom JM; Sihto H; Nupponen N; Joensuu H; Odén A; Gustavsson B; Kindblom LG; Nilsson B
Gastroenterology; 2006 May; 130(6):1573-81. PubMed ID: 16697720
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
[TBL] [Abstract][Full Text] [Related]
27. [c-kit and PDGFRA mutations in 60 cases of gastrointestinal stromal tumors (GISTs)].
He HY; Xiang YN; Li Y; Zhong HH; Wu BQ; Zheng J
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Jun; 37(3):320-4. PubMed ID: 15968329
[TBL] [Abstract][Full Text] [Related]
28. Aberrant methylation status of known methylation-sensitive CpG islands in gastrointestinal stromal tumors without any correlation to the state of c-kit and PDGFRA gene mutations and their malignancy.
Saito K; Sakurai S; Sano T; Sakamoto K; Asao T; Hosoya Y; Nakajima T; Kuwano H
Cancer Sci; 2008 Feb; 99(2):253-9. PubMed ID: 18271923
[TBL] [Abstract][Full Text] [Related]
29. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated.
Penzel R; Aulmann S; Moock M; Schwarzbach M; Rieker RJ; Mechtersheimer G
J Clin Pathol; 2005 Jun; 58(6):634-9. PubMed ID: 15917417
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic significance of DOG-1 and PKC-θ expression and c-Kit/PDGFRA mutations in gastrointestinal stromal tumours.
Wang C; Jin MS; Zou YB; Gao JN; Li XB; Peng F; Wang HY; Wu ZD; Wang YP; Duan XM
Scand J Gastroenterol; 2013 Sep; 48(9):1055-65. PubMed ID: 23862765
[TBL] [Abstract][Full Text] [Related]
31. The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs.
Sápi Z; Füle T; Hajdu M; Matolcsy A; Moskovszky L; Márk A; Sebestyén A; Bodoky G
Diagn Mol Pathol; 2011 Mar; 20(1):22-33. PubMed ID: 21326036
[TBL] [Abstract][Full Text] [Related]
32. Somatic mutational spectrum analysis in a prospective series of 104 gastrointestinal stromal tumors.
Guenat D; Deroo O; Magnin S; Chaigneau L; Monnien F; Borg C; Mougin C; Emile JF; Prétet JL
Oncol Rep; 2017 Mar; 37(3):1671-1681. PubMed ID: 28098915
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
Lasota J; Miettinen M
Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355
[TBL] [Abstract][Full Text] [Related]
34. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.
Boikos SA; Pappo AS; Killian JK; LaQuaglia MP; Weldon CB; George S; Trent JC; von Mehren M; Wright JA; Schiffman JD; Raygada M; Pacak K; Meltzer PS; Miettinen MM; Stratakis C; Janeway KA; Helman LJ
JAMA Oncol; 2016 Jul; 2(7):922-8. PubMed ID: 27011036
[TBL] [Abstract][Full Text] [Related]
35. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).
Lasota J; Miettinen M
Semin Diagn Pathol; 2006 May; 23(2):91-102. PubMed ID: 17193822
[TBL] [Abstract][Full Text] [Related]
36. Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors.
Yoo C; Ryu MH; Na YS; Ryoo BY; Park SR; Kang YK
Ann Oncol; 2014 Nov; 25(11):2272-2277. PubMed ID: 25149706
[TBL] [Abstract][Full Text] [Related]
37. Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor.
Namløs HM; Boye K; Mishkin SJ; Barøy T; Lorenz S; Bjerkehagen B; Stratford EW; Munthe E; Kudlow BA; Myklebost O; Meza-Zepeda LA
Mol Cancer Ther; 2018 Nov; 17(11):2473-2480. PubMed ID: 30097488
[TBL] [Abstract][Full Text] [Related]
38. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
39. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.
Agaimy A; Terracciano LM; Dirnhofer S; Tornillo L; Foerster A; Hartmann A; Bihl MP
J Clin Pathol; 2009 Jul; 62(7):613-6. PubMed ID: 19561230
[TBL] [Abstract][Full Text] [Related]
40. Differentially expressed proteins in gastrointestinal stromal tumors with KIT and PDGFRA mutations.
Kang HJ; Koh KH; Yang E; You KT; Kim HJ; Paik YK; Kim H
Proteomics; 2006 Feb; 6(4):1151-7. PubMed ID: 16402362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]